ClinicalTrials.gg
CompletedNCT00546572Updated Jul 14, 2011Results posted

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

A Phase 3 interventional study of 13 valent Pneumococcal Conjugate Vaccine and 23vPS in Pneumococcal Infections, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 58 sites in 2 countries. Open to participants aged 70 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-07-14.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
938
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
8th of 44
938 · median 328
Started
2007
with 5 others
Phase 3
19 of 44
none open now
Registered
8th of 44
by date
Lead sponsor
4 of 44
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 8th largest by enrollment, is one of 6 that started in 2007, is one of 19 in phase 3, and was the 8th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 70 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

This study will evaluate the safety, tolerability and immunogenicity of study vaccines 13vPnC and 23vPS in older, healthy subjects who have previously received a dose of 23vPS at least 5 years ago. It will also evaluate the safety, tolerability and immunogenicity to a dose of 13vPnC 1 year after the initial dose of study vaccine.

03

Conditions studied

  • Pneumococcal Infections
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female aged 70 years or older.
  • Documented vaccination with 1 dose of 23vPS at least 5 years previous.
  • Healthy.

Exclusion criteria

Exclusion Criteria:

  • Receipt of more than one dose of 23vPS prior to enrollment.
  • History of severe adverse reaction to a vaccine.
  • Immunodeficiency.
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
938 participants (actual)

Study arms

  • Experimental
    1

    Receives 13vPnC at year 0 and 13vPnC at year 1

    Biological: 13 valent Pneumococcal Conjugate Vaccine

  • Active comparator
    2

    Receives 23vPS at year 0 and 13vPnC at year 1

    Biological: 23vPS

Interventions

  • 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1

  • Biological23vPS

    0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1

06

What researchers measure

Primary outcomes

  1. Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)

    Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 1 month after Vax 1 / Year 0

  2. Percentage of Participants Achieving a ≥ 4-fold Rise for Serotype 6A OPA Titer for 13vPnC Relative to 23vPS (Vax 1 / Year 0)

    OPA titer for the 6A serotype measured for at least a 4-fold increase from the prevaccination to postvaccination blood sample collection. Exact 2-sided CI (Clopper and Pearson) based upon the observed percentage of participants.

    Time frame: Baseline, 1 month after Vax 1 / Year 0

Secondary outcomes

  1. Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC Relative to 23vPS (Vax 1 / Year 0)

    Antibody geometric mean titer as measured by OPA assay for the 6A pneumococcal serotype. Confidence intervals for the GMT are back transformation of a CI based on the Student t distribution for the mean logarithm of the titer.

    Time frame: 1 month after Vax 1 / Year 0

  2. Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)

    Antibody geometric mean titers as measured by OPA assays for the 13 serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1

  3. Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)

    Antibody geometric mean titers as measured by OPA assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1

  4. Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)

    Antibody geometric mean titer as measured by OPA assay for the 6A serotype. Confidence intervals (CI) for the GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titer.

    Time frame: 1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1

Other outcomes

  1. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)

    Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)

    Time frame: Days 1 through 14 / Year 0

  2. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)

    Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)

    Time frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1

  3. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)

    Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)

    Time frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1

  4. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )

    Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)

    Time frame: Days 1 through 14 / Year 1

  5. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)

    Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)

    Time frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1

  6. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)

    Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).

    Time frame: Days 1 through 14 / Year 0

  7. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)

    Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).

    Time frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1

  8. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)

    Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).

    Time frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1

  9. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)

    Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).

    Time frame: Days 1 through 14 / Year 1

  10. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)

    Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).

    Time frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1

07

Results

Posted May 30, 2011

Participant flow

Vax 1 / Year 0
Participant flow — Vax 1 / Year 0
Milestone13vPnC / 13vPnC23vPS / 13vPnC
Started464474
Received vax 1463473
Completed391404
Not completed7370
Withdrew: Randomized, not treated11
Withdrew: Withdrawal by subject32
Withdrew: Protocol violation34
Withdrew: Death22
Withdrew: Adverse event01
Withdrew: Lost to follow-up01
Withdrew: 6-month contact; withdraw before vax 26459
Vax 2 / Year 1
Participant flow — Vax 2 / Year 1
Milestone13vPnC / 13vPnC23vPS / 13vPnC
Started391404
Received vax 2391404
Completed387402
Not completed42
Withdrew: Other11
Withdrew: Adverse event10
Withdrew: Vax 2; withdraw before 6-month contact21

Outcome measures

PrimaryPneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)

Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
1 month after Vax 1 / Year 0
Reported as:
Geometric mean · geometric mean titer
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
geometric mean titer13vPnC23vPS
Serotype 181 (68.4 to 95.9)55 (46.2 to 64.8)
Serotype 355 (47.7 to 62.9)49 (42.9 to 56.9)
Serotype 4545 (441.9 to 672.3)203 (157.1 to 262.2)
Serotype 572 (59.7 to 86.6)36 (29.5 to 43.1)
Serotype 6B1261 (1024.7 to 1552.6)417 (330.5 to 526.7)
Serotype 7F245 (191.9 to 312.4)160 (123.5 to 207.9)
Serotype 9V181 (138.0 to 237.0)90 (67.8 to 119.7)
Serotype 14280 (227.5 to 345.5)285 (228.9 to 354.3)
Serotype 18C907 (761.9 to 1080.1)481 (385.1 to 600.7)
Serotype 19A354 (307.7 to 408.4)200 (170.0 to 234.4)
Serotype 19F333 (273.2 to 404.8)214 (174.3 to 262.8)
Serotype 23F158 (126.0 to 198.6)43 (34.2 to 53.5)
Statistical analysis
  • 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.5 · 95% CI 1.17 to 1.88Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC - 23vPS).
  • 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.1 · 95% CI 0.91 to 1.35Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC - 23vPS).
  • 13vPnC vs 23vPS · Ratio of geometric mean titer: 2.7 · 95% CI 1.93 to 3.74Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC - 23vPS).
  • 13vPnC vs 23vPS · Ratio of geometric mean titer: 2.0 · 95% CI 1.55 to 2.63Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC - 23vPS).
  • 13vPnC vs 23vPS · Ratio of geometric mean titer: 3.0 · 95% CI 2.21 to 4.13Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC - 23vPS).
  • 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.5 · 95% CI 1.07 to 2.18Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC - 23vPS).
  • 13vPnC vs 23vPS · Ratio of geometric mean titer: 2.0 · 95% CI 1.36 to 2.97Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC - 23vPS).
  • 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.0 · 95% CI 0.73 to 1.33Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC - 23vPS).
  • 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.9 · 95% CI 1.42 to 2.50Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC - 23vPS).
  • 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.8 · 95% CI 1.43 to 2.20Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC - 23vPS).
  • 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.6 · 95% CI 1.17 to 2.06Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC - 23vPS).
  • 13vPnC vs 23vPS · Ratio of geometric mean titer: 3.7 · 95% CI 2.69 to 5.09Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC - 23vPS).
PrimaryPercentage of Participants Achieving a ≥ 4-fold Rise for Serotype 6A OPA Titer for 13vPnC Relative to 23vPS (Vax 1 / Year 0)

OPA titer for the 6A serotype measured for at least a 4-fold increase from the prevaccination to postvaccination blood sample collection. Exact 2-sided CI (Clopper and Pearson) based upon the observed percentage of participants.

Time frame:
Baseline, 1 month after Vax 1 / Year 0
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving a ≥ 4-fold Rise for Serotype 6A OPA Titer for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
observed percentage of participants13vPnC23vPS
Percentage of Participants Achieving a ≥ 4-fold Rise for Serotype 6A OPA Titer for 13vPnC Relative to 23vPS (Vax 1 / Year 0)71.1 (66.4 to 75.4)27.3 (23.0 to 31.8)
Statistical analysis
  • 13vPnC vs 23vPS · Difference in proportions: 43.8 · 95% CI 37.4 to 49.9Exact 2-sided CI (based on Chan and Zhang) for the difference in proportions, 13vPnC - 23vPS expressed as a percentage.
SecondaryPneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC Relative to 23vPS (Vax 1 / Year 0)

Antibody geometric mean titer as measured by OPA assay for the 6A pneumococcal serotype. Confidence intervals for the GMT are back transformation of a CI based on the Student t distribution for the mean logarithm of the titer.

Time frame:
1 month after Vax 1 / Year 0
Reported as:
Geometric mean · geometric mean titer
Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
geometric mean titer13vPnC23vPS
Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC Relative to 23vPS (Vax 1 / Year 0)903 (726.7 to 1121.3)94 (74.1 to 118.5)
Statistical analysis
  • 13vPnC vs 23vPS · Ratio of geometric mean titer: 9.6 · 95% CI 7.00 to 13.26Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC - 23vPS).
SecondaryPneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)

Antibody geometric mean titers as measured by OPA assays for the 13 serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1
Reported as:
Geometric mean · geometric mean titer
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
geometric mean titer13vPnC13vPnC / 13vPnC
Serotype 179 (65.3 to 94.6)76 (64.8 to 89.7)
Serotype 355 (47.2 to 64.0)55 (48.4 to 63.1)
Serotype 4614 (489.8 to 768.8)487 (393.9 to 603.3)
Serotype 569 (56.2 to 84.2)57 (46.9 to 68.5)
Serotype 6A971 (771.0 to 1222.1)1169 (974.0 to 1403.0)
Serotype 6B1358 (1085.4 to 1700.2)1590 (1316.9 to 1919.8)
Serotype 7F222 (170.2 to 290.2)180 (138.1 to 233.8)
Serotype 9V187 (139.3 to 250.4)166 (124.2 to 220.8)
Serotype 14265 (209.9 to 333.6)241 (194.4 to 299.1)
Serotype 18C918 (763.4 to 1104.3)1003 (850.2 to 1182.1)
Serotype 19A349 (299.7 to 405.5)341 (297.2 to 390.5)
Serotype 19F329 (265.6 to 408.6)322 (266.3 to 389.6)
Serotype 23F167 (130.9 to 213.0)309 (251.6 to 380.1)
Statistical analysis
  • 13vPnC vs 13vPnC / 13vPnC · Geometric mean fold rise: 1.0 · 95% CI 0.85 to 1.10Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.
  • 13vPnC vs 13vPnC / 13vPnC · Geometric mean fold rise: 1.0 · 95% CI 0.91 to 1.11Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.
  • 13vPnC vs 13vPnC / 13vPnC · Geometric mean fold rise: 0.8 · 95% CI 0.68 to 0.92Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.
  • 13vPnC vs 13vPnC / 13vPnC · Geometric mean fold rise: 0.8 · 95% CI 0.73 to 0.94Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.
  • 13vPnC vs 13vPnC / 13vPnC · Geometric mean fold rise: 1.2 · 95% CI 1.03 to 1.40Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.
  • 13vPnC vs 13vPnC / 13vPnC · Geometric mean fold rise: 1.2 · 95% CI 1.02 to 1.35Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.
  • 13vPnC vs 13vPnC / 13vPnC · Geometric mean fold rise: 0.8 · 95% CI 0.65 to 1.01Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.
  • 13vPnC vs 13vPnC / 13vPnC · Geometric mean fold rise: 0.9 · 95% CI 0.69 to 1.15Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.
  • 13vPnC vs 13vPnC / 13vPnC · Geometric mean fold rise: 0.9 · 95% CI 0.79 to 1.05Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.
  • 13vPnC vs 13vPnC / 13vPnC · Geometric mean fold rise: 1.1 · 95% CI 0.97 to 1.23Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.
  • 13vPnC vs 13vPnC / 13vPnC · Geometric mean fold rise: 1.0 · 95% CI 0.89 to 1.07Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.
  • 13vPnC vs 13vPnC / 13vPnC · Geometric mean fold rise: 1.0 · 95% CI 0.83 to 1.15Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.
  • 13vPnC vs 13vPnC / 13vPnC · Geometric mean fold rise: 1.9 · 95% CI 1.60 to 2.14Confidence intervals are back transformations of a CI based on the student t distribution for the mean logarithm of the titers.
SecondaryPneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)

Antibody geometric mean titers as measured by OPA assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1
Reported as:
Geometric mean · geometric mean titers
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
geometric mean titers13vPnC / 13vPnC23vPS
Serotype 176 (64.9 to 89.5)55 (46.2 to 64.8)
Serotype 355 (47.9 to 62.0)49 (42.9 to 56.9)
Serotype 4472 (383.5 to 580.2)203 (157.1 to 262.2)
Serotype 556 (46.6 to 67.7)36 (29.5 to 43.1)
Serotype 6B1565 (1306.1 to 1875.9)417 (330.5 to 526.7)
Serotype 7F185 (142.9 to 239.7)160 (123.5 to 207.9)
Serotype 9V158 (119.5 to 209.5)90 (67.8 to 119.7)
Serotype 14238 (192.3 to 293.8)285 (228.9 to 354.3)
Serotype 18C975 (829.0 to 1147.3)481 (385.1 to 600.7)
Serotype 19A339 (296.4 to 386.9)200 (170.0 to 234.4)
Serotype 19F311 (257.1 to 375.9)214 (174.3 to 262.8)
Serotype 23F310 (254.1 to 378.0)43 (34.2 to 53.5)
Statistical analysis
  • 13vPnC / 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.4 · 95% CI 1.10 to 1.76Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(13vPnC / 13vPnC )- (23vPS)\].
  • 13vPnC / 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.1 · 95% CI 0.91 to 1.34Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(13vPnC / 13vPnC )- (23vPS)\].
  • 13vPnC / 13vPnC vs 23vPS · Ratio of geometric mean titer: 2.3 · 95% CI 1.66 to 3.25Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(13vPnC / 13vPnC )- (23vPS)\].
  • 13vPnC / 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.6 · 95% CI 1.21 to 2.06Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(13vPnC / 13vPnC )- (23vPS)\].
  • 13vPnC / 13vPnC vs 23vPS · Ratio of geometric mean titer: 3.8 · 95% CI 2.78 to 5.07Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(13vPnC / 13vPnC )- (23vPS)\].
  • 13vPnC / 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.2 · 95% CI 0.80 to 1.67Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(13vPnC / 13vPnC )- (23vPS)\].
  • 13vPnC / 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.8 · 95% CI 1.18 to 2.62Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(13vPnC / 13vPnC )- (23vPS)\].
  • 13vPnC / 13vPnC vs 23vPS · Ratio of geometric mean titer: 0.8 · 95% CI 0.62 to 1.13Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(13vPnC / 13vPnC )- (23vPS)\].
  • 13vPnC / 13vPnC vs 23vPS · Ratio of geometric mean titer: 2.0 · 95% CI 1.53 to 2.69Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(13vPnC / 13vPnC )- (23vPS)\].
  • 13vPnC / 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.7 · 95% CI 1.37 to 2.10Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(13vPnC / 13vPnC )- (23vPS)\].
  • 13vPnC / 13vPnC vs 23vPS · Ratio of geometric mean titer: 1.5 · 95% CI 1.09 to 1.93Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(13vPnC / 13vPnC )- (23vPS)\].
  • 13vPnC / 13vPnC vs 23vPS · Ratio of geometric mean titer: 7.3 · 95% CI 5.36 to 9.82Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(13vPnC / 13vPnC )- (23vPS)\].
SecondaryPneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)

Antibody geometric mean titer as measured by OPA assay for the 6A serotype. Confidence intervals (CI) for the GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titer.

Time frame:
1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1
Reported as:
Geometric mean · geometric mean titer
Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
geometric mean titer13vPnC / 13vPnC23vPS
Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)1134 (943.6 to 1363.7)94 (74.1 to 118.5)
Statistical analysis
  • 13vPnC / 13vPnC vs 23vPS · Ratio of geometric mean titer: 12.1 · 95% CI 8.92 to 16.44Confidence intervals for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(13vPnC / 13vPnC )- (23vPS)\].
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)

Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)

Time frame:
Days 1 through 14 / Year 0
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
percentage of participants13vPnC23vPS
Redness: Any (n=306, 324)10.822.2
Redness: Mild (n=304, 311)9.513.5
Redness: Moderate (n=301, 314)4.711.5
Redness: Severe (n=299, 310)1.74.8
Swelling: Any (n=307, 333)10.423.1
Swelling: Mild (n=305, 315)8.914.0
Swelling: Moderate (n=299, 323)4.013.6
Swelling: Severe (n=297, 310)0.04.8
Pain: Any (n=362, 383)51.758.5
Pain: Mild (n=359, 377)50.154.1
Pain: Moderate (n=306, 330)7.523.6
Pain: Severe (n=299, 306)1.32.3
Limitation of arm movement: Any (n=313, 326)10.527.6
Limitation of arm movement: Mild (n=312, 322)10.325.2
Limitation of arm movement: Moderate (n=297, 303)0.32.6
Limitation of arm movement: Severe (n=298, 305)0.73.0
Statistical analysis
  • 13vPnC vs 23vPS · Chan & Zhang · p = <0.001 · Difference in proportions: -11.4 · 95% CI -17.3 to -5.6Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = 0.129 · Difference in proportions: -4.0 · 95% CI -9.1 to 1.1Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = 0.002 · Difference in proportions: -6.8 · 95% CI -11.3 to -2.3Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = 0.028 · Difference in proportions: -3.2 · 95% CI -6.3 to -0.3Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = <0.001 · Difference in proportions: -12.7 · 95% CI -18.5 to -7.0Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = 0.048 · Difference in proportions: -5.1 · 95% CI -10.2 to -0.1Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = <0.001 · Difference in proportions: -9.6 · 95% CI -14.2 to -5.1Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = <0.001 · Difference in proportions: -4.8 · 95% CI -7.9 to -2.7Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = 0.062 · Chan & zhang: -6.8 · 95% CI -14.0 to 0.4Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = 0.284 · Difference in proportions: -4.0 · 95% CI -11.3 to 3.3Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = <0.001 · Difference in proportions: -16.1 · 95% CI -21.7 to -10.6Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = 0.539 · Difference in proportions: -0.9 · 95% CI -3.5 to 1.4Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = <0.001 · Difference in proportions: -17.1 · 95% CI -23.1 to -11.1Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = <0.001 · Difference in proportions: -14.9 · 95% CI -20.8 to -9.0Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = 0.020 · Difference in proportions: -2.3 · 95% CI -4.8 to -0.4Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Limitation of arm movement: any; differe · p = 0.042 · Difference in proportions: -2.3 · 95% CI -4.9 to -0.1Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)

Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)

Time frame:
Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
percentage of participants13vPnC13vPnC / 13vPnC
Redness: Any (n=185, 185)9.712.4
Redness: Mild (n=182, 182)8.26.0
Redness: Moderate (n=182, 182)4.47.1
Redness: Severe (n=179, 179)1.11.7
Swelling: Any (n=185, 185)9.210.8
Swelling: Mild (n=182, 182)6.68.8
Swelling: Moderate (n=179, 179)3.42.8
Swelling: Severe (n=177, 177)0.00.0
Pain: Any (n=258, 258)55.057.4
Pain: Mild (n=251, 251)53.054.2
Pain: Moderate (n=187, 187)8.611.2
Pain: Severe (n=179, 179)1.70.6
Limitation of arm movement: Any (n=195, 195)9.713.3
Limitation of arm movement: Mild (n=194, 194)9.313.4
Limitation of arm movement: Moderate (n=178, 178)0.60.6
Limitation of arm movement: Severe (n=178, 178)0.60.0
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)

Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)

Time frame:
Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
percentage of participants23vPS13vPnC / 13vPnC
Redness: Any (n=324, 236)22.212.7
Redness: Mild (n=311, 233)13.56.9
Redness: Moderate (n=314, 231)11.56.9
Redness: Severe (n=310, 227)4.81.8
Swelling: Any (n=333, 236)23.112.3
Swelling: Mild (n=315, 234)14.010.3
Swelling: Moderate (n=323, 229)13.63.5
Swelling: Severe (n=310, 227)4.80.9
Pain: Any (n=383, 297)58.558.2
Pain: Mild (n=377, 291)54.154.3
Pain: Moderate (n=330, 239)23.613.0
Pain: Severe (n=306, 226)2.30.4
Limitation of arm movement: Any (n=326, 247)27.616.2
Limitation of arm movement: Mild (n=322, 245)25.215.5
Limitation of arm movement: Moderate (n=303, 228)2.60.9
Limitation of arm movement: Severe (n=305, 228)3.00.9
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )

Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)

Time frame:
Days 1 through 14 / Year 1
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
percentage of participants13vPnC / 13vPnC23vPS / 13vPnC
Redness: Any (n=236, 228)12.710.1
Redness: Mild (n=233, 226)6.98.8
Redness: Moderate (n=231, 223)6.93.6
Redness: Severe (n=227, 222)1.80.9
Swelling: Any (n=236, 241)12.314.1
Swelling: Mild (n=234, 236)10.311.9
Swelling: Moderate (n=229, 229)3.54.8
Swelling: Severe (n=227, 222)0.90.5
Pain: Any (n=297, 302)58.256.6
Pain: Mild (n=291, 297)54.353.5
Pain: Moderate (n=239, 236)13.013.1
Pain: Severe (n=226, 221)0.40.9
Limitation of arm movement: Any (n=247, 251)16.219.9
Limitation of arm movement: Mild (n=245, 249)15.518.9
Limitation of arm movement: Moderate (n=228, 222)0.90.9
Limitation of arm movement: Severe (n=228, 222)0.91.4
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)

Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)

Time frame:
Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
percentage of participants13vPnC23vPS / 13vPnC
Redness: Any (n=306, 228)10.810.1
Redness: Mild (n=304, 226)9.58.8
Redness: Moderate (n=301, 223)4.73.6
Redness: Severe (n=299, 222)1.70.9
Swelling: Any (n=307, 241)10.414.1
Swelling: Mild (n=305, 236)8.911.9
Swelling: Moderate (n=299, 229)4.04.8
Swelling: Severe (n=297, 222)0.00.5
Pain: Any (n=362, 302)51.756.6
Pain: Mild (n=359, 297)50.153.5
Pain: Moderate (n=306, 236)7.513.1
Pain: Severe (n=299, 221)1.30.9
Limitation of arm movement: Any (n=313, 251)10.519.9
Limitation of arm movement: Mild (n=312, 249)10.318.9
Limitation of arm movement: Moderate (n=297, 222)0.30.9
Limitation of arm movement: Severe (n=298, 222)0.71.4
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)

Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).

Time frame:
Days 1 through 14 / Year 0
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
percentage of participants13vPnC23vPS
Fever: Any ≥38 degrees C (n=299, 309)1.04.2
Fever: Mild ≥38 but <38.5 degrees C (n=299, 303)1.02.0
Fever: Moderate ≥38.5 but <39 degrees C(n=297,301)0.00.0
Fever: Severe ≥39 but ≤40 degrees C (n=297, 301)0.00.3
Potentially life-threatening >40C (n=297, 307)0.02.0
Fatigue (n=350, 367)34.043.3
Headache (n=329, 331)23.726.0
Chills (n=305, 312)7.911.2
Rash (n=303, 323)7.316.4
Vomiting (n=300, 304)1.71.3
Decreased appetite (n=317, 313)10.411.5
New muscle pain (n=345, 358)36.844.7
Aggravated muscle pain (n=320, 334)20.627.5
New joint pain (n=310, 323)12.614.9
Aggravated joint pain (n=310, 322)11.616.5
Statistical analysis
  • 13vPnC vs 23vPS · Chan & Zhang · p = 0.034 · Difference in proportions: -7.9 · 95% CI -15.2 to -0.6Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
  • 13vPnC vs 23vPS · Chan & Zhang · p = 0.039 · Difference in proportions: -6.9 · 95% CI -13.6 to -0.3Exact 2-sided confidence interval and corresponding p-value (based on Chan \& Zhang) for the difference in proportions, \[13vPnC\] - \[23vPS\], expressed as a percentage.
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)

Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).

Time frame:
Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
percentage of participants13vPnC13vPnC / 13vPnC
Fever: Any ≥38 degrees C (n=179, 179)1.72.2
Fever: Mild ≥38 but <38.5 degrees C (n=179, 179)1.70.6
Fever: Moderate ≥38.5 but <39 degrees C(n=177,177)0.00.0
Fever: Severe ≥39 but ≤40 degrees C (n=177, 177)0.00.6
Potentially life-threatening >40C (n=177, 177)0.01.1
Fatigue (n=215, 215)33.528.4
Headache (n=200, 200)23.019.0
Chills (n=182, 182)9.34.4
Rash (n=183, 183)8.26.0
Vomiting (n=178, 178)1.10.0
Decreased appetite (n=190, 190)8.47.9
New muscle pain (n=219, 219)37.935.6
Aggravated muscle pain (n=198, 198)20.716.2
New joint pain (n=187, 187)11.27.5
Aggravated joint pain (n=188, 188)11.210.1
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)

Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).

Time frame:
Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
percentage of participants23vPS13vPnC / 13vPnC
Fever: Any ≥38 degrees C (n=309, 229)4.23.5
Fever: Mild ≥38 but <38.5 degrees C (n=303, 227)2.00.9
Fever: Moderate ≥38.5 but <39 degrees C(n=301,227)0.00.9
Fever: Severe ≥39 but ≤40 degrees C (n=301, 226)0.30.4
Potentially life-threatening >40C (n=307, 227)2.01.3
Fatigue (n=367, 255)43.328.6
Headache (n=331, 246)26.019.1
Chills (n=312, 234)11.27.3
Rash (n=323, 232)16.46.0
Vomiting (n=304, 226)1.30.4
Decreased appetite (n=313, 237)11.58.9
New muscle pain (n=358, 260)44.734.6
Aggravated muscle pain (n=334, 245)27.518.0
New joint pain (n=323, 238)14.910.5
Aggravated joint pain (n=322, 239)16.512.6
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)

Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).

Time frame:
Days 1 through 14 / Year 1
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
percentage of participants13vPnC / 13vPnC23vPS / 13vPnC
Fever: Any ≥38 degrees C (n=229, 224)3.52.2
Fever: Mild ≥38 but <38.5 degrees C (n=227, 224)0.91.8
Fever: Moderate ≥38.5 but <39 degrees C(n=227,221)0.90.0
Fever: Severe ≥39 but ≤40 degrees C (n=226, 222)0.40.5
Potentially life-threatening >40C (n=227, 221)1.30.5
Fatigue (n=255, 265)28.634.3
Headache (n=246, 248)19.122.6
Chills (n=234, 233)7.39.9
Rash (n=232, 226)6.07.1
Vomiting (n=226, 226)0.43.1
Decreased appetite (n=237, 230)8.97.4
New muscle pain (n=260, 263)34.635.0
Aggravated muscle pain (n=245, 248)18.021.0
New joint pain (n=238, 234)10.512.0
Aggravated joint pain (n=239, 231)12.611.7
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)

Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).

Time frame:
Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
percentage of participants13vPnC23vPS / 13vPnC
Fever: Any ≥38 degrees C (n=299, 224)1.02.2
Fever: Mild ≥38 but <38.5 degrees C (n=299, 224)1.01.8
Fever: Moderate ≥38.5 but <39 degrees C(n=297,221)0.00.0
Fever: Severe ≥39 but ≤40 degrees C (n=297, 222)0.00.5
Potentially life-threatening >40C (n=297, 221)0.00.5
Fatigue (n=350, 265)34.034.3
Headache (n=329, 248)23.722.6
Chills (n=305, 233)7.99.9
Rash (n=303, 226)7.37.1
Vomiting (n=300, 226)1.73.1
Decreased appetite (n=317, 230)10.47.4
New muscle pain (n=345, 263)36.835.0
Aggravated muscle pain (n=320, 248)20.621.0
New joint pain (n=310, 234)12.612.0
Aggravated joint pain (n=310, 231)11.611.7

Adverse events

Collected over Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC (Vax 1 / Year 0) 1 Month After Vaccination—3/463 (0.6%)234/463 (50.5%)
23vPS (Vax 1 / Year 0) 1 Month After Vaccination—8/473 (1.7%)275/473 (58.1%)
13vPnC 6-M FU (Vax 1 / Year 0)—27/463 (5.8%)60/463 (13%)
23vPS 6-M FU (Vax 1 / Year 0)—26/473 (5.5%)59/473 (12.5%)
13vPnC / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination—4/391 (1%)191/391 (48.8%)
23vPS / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination—7/404 (1.7%)189/404 (46.8%)
13vPnC / 13vPnC 6-M FU (Vax 2 / Year 1)—17/391 (4.3%)29/391 (7.4%)
23vPS / 13vPnC 6-M FU (Vax 2 / Year 1)—21/404 (5.2%)30/404 (7.4%)
Most frequent serious events
Showing 10 of 97
Most frequent serious events
Event13vPnC (Vax 1 / Year 0) 1 Month After Vaccination23vPS (Vax 1 / Year 0) 1 Month After Vaccination13vPnC 6-M FU (Vax 1 / Year 0)23vPS 6-M FU (Vax 1 / Year 0)13vPnC / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination23vPS / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination13vPnC / 13vPnC 6-M FU (Vax 2 / Year 1)23vPS / 13vPnC 6-M FU (Vax 2 / Year 1)
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4632/4733/4634/4731/3910/4043/3910/404
Atrial fibrillationCardiac disorders1/4630/4731/4630/4730/3910/4040/3913/404
Angina pectorisCardiac disorders1/4631/4733/4630/4731/3910/4040/3910/404
BradycardiaCardiac disorders0/4630/4730/4630/4730/3910/4042/3910/404
PneumoniaInfections and infestations0/4631/4730/4631/4730/3910/4040/3912/404
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4630/4730/4632/4730/3910/4040/3912/404
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4630/4730/4631/4730/3911/4040/3912/404
Coronary artery diseaseCardiac disorders0/4630/4732/4631/4730/3910/4040/3910/404
Myocardial infarctionCardiac disorders0/4630/4732/4631/4730/3910/4040/3910/404
OsteoarthritisMusculoskeletal and connective tissue disorders0/4630/4730/4632/4730/3911/4041/3910/404
Most frequent other events
Showing 10 of 339
Most frequent other events
Event13vPnC (Vax 1 / Year 0) 1 Month After Vaccination23vPS (Vax 1 / Year 0) 1 Month After Vaccination13vPnC 6-M FU (Vax 1 / Year 0)23vPS 6-M FU (Vax 1 / Year 0)13vPnC / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination23vPS / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination13vPnC / 13vPnC 6-M FU (Vax 2 / Year 1)23vPS / 13vPnC 6-M FU (Vax 2 / Year 1)
Pain (Any)Skin and subcutaneous tissue disorders187/362224/383——173/297171/302——
Pain (Any)Skin and subcutaneous tissue disorders142/2580/473——148/2580/404——
Pain (Mild)Skin and subcutaneous tissue disorders180/359204/377——158/291159/297——
Pain (Mild)Skin and subcutaneous tissue disorders133/2510/473——136/2510/404——
New generalized muscle painGeneral disorders127/345160/358——90/26092/263——
FatigueGeneral disorders119/350159/367——73/25591/265——
New generalized muscle painGeneral disorders83/2190/473——78/2190/404——
FatigueGeneral disorders72/2150/473——61/2150/404——
Limitation of arm movement (Any)Skin and subcutaneous tissue disorders33/31390/326——40/24750/251——
Aggravated generalized muscle painGeneral disorders66/32092/334——44/24552/248——

Baseline characteristics

Age Continuous
Age Continuous(years)13vPnC23vPSTotal
Mean76.7 ± 4.676.7 ± 4.576.7 ± 4.6
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC23vPSTotal
Female221235456
Male242238480
08

Study locations

58 sites
  • Pfizer Investigational Site
    Mobile, Alabama 36608, United States
  • Pfizer Investigational Site
    Mesa, Arizona 85203, United States
  • Pfizer Investigational Site
    Mesa, Arizona 85213, United States
  • Pfizer Investigational Site
    Fountain Valley, California 92708, United States
  • Pfizer Investigational Site
    Denver, Colorado 80262, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut 06708, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33761, United States
  • Pfizer Investigational Site
    Coral Gables, Florida 33134, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32216, United States
  • Pfizer Investigational Site
    Pinellas Park, Florida 33781, United States
  • Pfizer Investigational Site
    Tampa, Florida 33614, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30305, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30328, United States
  • Pfizer Investigational Site
    Stockbridge, Georgia 30328, United States
  • Pfizer Investigational Site
    Shawnee Mission, Kansas 66128, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40536, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21209, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota 55417, United States
  • Pfizer Investigational Site
    Rochester, Minnesota 55905, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63104, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63141, United States
  • Pfizer Investigational Site
    Butte, Montana 59701, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89146, United States
  • Pfizer Investigational Site
    Rochester, New York 14642, United States
  • Pfizer Investigational Site
    Cary, North Carolina 27511, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28209, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27705, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27710, United States
  • Pfizer Investigational Site
    Hickory, North Carolina 28601, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina 27612, United States
  • Pfizer Investigational Site
    Salisbury, North Carolina 28144, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Pfizer Investigational Site
    Fargo, North Dakota 58103, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45229, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45236, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44195, United States
  • Pfizer Investigational Site
    Corvallis, Oregon 97330, United States
  • Pfizer Investigational Site
    Eugene, Oregon 97401, United States
  • Pfizer Investigational Site
    Carnegie, Pennsylvania 15106, United States
  • Pfizer Investigational Site
    Downington, Pennsylvania 19335, United States
  • Pfizer Investigational Site
    Grove City, Pennsylvania 16127, United States
  • Pfizer Investigational Site
    Penndel, Pennsylvania 19047, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • Pfizer Investigational Site
    Upper St. Clair, Pennsylvania 15241, United States
  • Pfizer Investigational Site
    Greer, South Carolina 29651, United States
  • Pfizer Investigational Site
    Mt. Pleasant, South Carolina 29464, United States
  • Pfizer Investigational Site
    Bristol, Tennessee 37620, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232, United States
  • Pfizer Investigational Site
    Austin, Texas 78705, United States
  • Pfizer Investigational Site
    Norfolk, Virginia 23507, United States
  • Pfizer Investigational Site
    Seattle, Washington 998101, United States
  • Pfizer Investigational Site
    Arlov, 23234, Sweden
  • Pfizer Investigational Site
    Boden, 96131, Sweden
  • Pfizer Investigational Site
    Degeberga, 29731, Sweden
  • Pfizer Investigational Site
    Gothenburg, 40014, Sweden
  • Pfizer Investigational Site
    Malmoe, 21120, Sweden
  • Pfizer Investigational Site
    Umea, 90736, Sweden
  • Pfizer Investigational Site
    Uppsala, 75185, Sweden
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2007
First posted
Oct 19, 2007
Start
Nov 2007
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
May 30, 2011
Last update
Jul 14, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00546572
First posted
Oct 19, 2007
Start date
Nov 2007
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
May 30, 2011
Last update
Jul 14, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion